What Hu-manity.co's $5.5M Bought — and the Five Gates It Buys RDCO
The question
"What did Hu-manity.co's $5.5M actually buy? Failure-mode autopsy of burn-rate vs milestone-achievement curve 2018-2024 to yield concrete go/no-go gates for the RDCO data-sovereignty bet. May require warm intro to Richie Etwaru."
Context: auto-promoted from the open-follow-ups list of [[2026-05-18-hu-manity-co-zombie-status]], which established Hu-manity as the RDCO bet's canonical cautionary tale but did not reconstruct the spend-vs-delivery curve.
What we already know (from the vault)
- [[2026-05-18-hu-manity-co-zombie-status]] — the parent. Verdict: pivoted-away half-zombie, re-scored 0/3 on the DS+VBC+PI rubric. Stuck at $5.5M pre-seed since 2018, no follow-on in 8 years. Last press release May 8, 2019. Product today is "Privacy Experience™" cookie/consent SaaS. Named five failure modes (rhetoric-without-revenue; no-payer-side-revenue → commodity SaaS collapse; blockchain-as-distraction; founder-horizon vs payer-cycle mismatch; the human-rights frame selecting the wrong investors).
- [[2026-05-11-patient-data-sovereignty-competitor-scan]] — the anchor. Verdict A. Clean white space; Hu-manity was the closest thesis match in the entire scan before its re-score to 0/3.
- [[2026-05-10-data-sovereignty-outcome-procurement-bet-architecture]] — the bet being gated. Phase 1 = Variant A MVP, months 0-6, $50-150K self-funded, goal one paid pilot at $10-30K. Notably, its "What Ray builds" list ranks data-ingestion MCPs as priority #1 — this brief argues that ordering is the Hu-manity shape and should invert.
- [[2026-07-09-patient-data-rights-startups-2024-2026-scan]] — the load-bearing recent finding: the patient-anchored-PHR layer is table stakes a competitor can buy for ~$18M (Novellia's June 2026 Series A). The DS leg commoditizes; the VBC+PI economics remain uncrowded.
- The whole close-analog cohort pivoted the same direction — [[2026-05-23-picnichealth-thumbprint-vbc-trajectory]], [[2026-05-22-embleema-status-check-2026]], [[2026-05-24-health-wizz-status-rescore]] all drifted from the wedge toward pharma RWE. Hu-manity is not an idiosyncratic failure; it is the first instance of a repeated pattern.
What the web says
The headline finding: the burn curve is not reconstructible — but a milestone-commitment-vs-silence timeline is, and it is more useful.
- The stated activation threshold was ~1,000,000 users. TechCrunch's Sept 6, 2018 #My31 launch coverage reports the phased plan verbatim: "the first 25,000 sign ups will get a premium printed title delivered to their homes," and the company projected reaching "a million users" as the threshold at which it could "begin to negotiate a cost structure with data buyers." (TechCrunch, 2018-09-06). This is the single most diagnostic public fact in the record: no revenue mechanism activated until a consumer-scale threshold was crossed, on pre-seed money.
- The enterprise revenue leg was scheduled for Q1 2019 — "starting in the healthcare industry" (2018 launch coverage). No public evidence it shipped or booked.
- Achievement against those thresholds was never publicly reported. No #My31 user count was ever disclosed after launch — not at 25,000, not at any number. The silence is the datapoint.
- The milestone news window was ~8 months wide. Raise Sept 2018 → IBM Blockchain co-announcement → Betterpath acquisition (April 2019) → last press release May 8, 2019 (Larry Smarr advisor). Then nothing, for seven years and counting (parent brief, verified).
- hu-manity.co is materially more frozen than the May 18 read suggested. Re-fetched 2026-07-17: footer reads verbatim
"© 2022, Hu-manity.co | Terms of Service | Privacy Policy | All Rights Reserved."Product = Privacy Experience™ (AI contract analysis for privacy compliance). Healthcare/patient-data-rights language: none found. #My31: not mentioned anywhere. Most recent cited evidence on the page is from 2020 reports. The May 18 brief recorded residual "human data rights" trust rhetoric; on the current homepage even the rhetorical layer has been stripped. - Richie Etwaru is now Chairman, Co-founder & CEO of Mobeus — a Sparta, NJ spatial-computing company that emerged from stealth in 2022 with $24M, co-founded with Mike Sutcliff (former group CEO, Accenture Digital). His LinkedIn headline is "CEO @Mobeus." (Crunchbase person profile, ROI-NJ, 2023-04-05, Forbes Technology Council profile)
- NJ trade-press attributes the stall to COVID — coverage of the Mobeus story states Hu-manity raised $5.5M from angel investors and that "when the COVID pandemic started, the company was one of the victims of the changed economy." Confidence: MEDIUM. The ROI-NJ primary returned HTTP 403 on direct fetch; this claim rests on a search-index snippet, not a verified primary read. Flagged, not retried. Do not treat as established until a primary read confirms it.
What is NOT establishable, explicitly:
- No burn rate, ever. Hu-manity is a private company whose only round was a 2018 pre-seed. There is no 10-K, no S-1, no disclosed P&L. A Form D (if filed) would confirm raise date/amount/investor count but discloses nothing about spend.
- No headcount series. Only two datapoints exist: Tracxn's July 1, 2024 update (20 employees) and the LinkedIn 11-50 band. There is no 2018-2023 series, so even a headcount-derived burn proxy cannot be constructed.
- No milestone-achievement data. Targets were published; results never were.
Therefore: the burn-rate-vs-milestone-achievement curve requested by this question is not reconstructible from public sources, and would not become reconstructible from any desk-research method. Anything resembling that curve would be fabrication. What follows is built only on the commitment-vs-silence timeline, which is real.
Convergences and contradictions
- Convergence, strengthened: every independent surface (frozen 2022 footer, dead-since-2019 press archive, no follow-on capital in 8 years, founder running a different company since 2022, zero healthcare language remaining) agrees the healthcare-data-sovereignty thesis was abandoned, not paused. The May 18 "half-zombie" verdict holds and hardens.
- Contradiction with the May 18 brief (a real correction): May 18 recorded that "Richie Etwaru is still listed as Chairman/Co-CEO on the company page… No reports of formal exit," and read the marketing layer as retaining human-data-rights rhetoric. Both need amending. The company page listing is stale metadata: Etwaru has been CEO of a $24M-funded unrelated company since 2022. And the current homepage retains no healthcare rhetoric. Founder attention departed roughly four years before the May 18 snapshot implied.
- The sharpest contradiction is with the "founder couldn't execute" reading — and it isolates the variable. The same founder raised $24M in 2022 — 4.4x the entire Hu-manity raise — four years later, in a tighter macro, for an unrelated thesis, alongside a former Accenture Digital group CEO. Capability and capital access were not the binding constraint. The patient-data-sovereignty thesis specifically could not clear the bar. That is a market verdict on the thesis, not a verdict on the people. It is also exactly why the autopsy generalizes to RDCO: we cannot assume better execution routes around it.
Synthesis for RDCO
The finding that reframes the question. The autopsy's premise — that $5.5M was burned against a milestone curve we could trace — is the wrong model of what happened. The public record supports a different and more alarming shape: Hu-manity never reached the point where burn-vs-milestone was the operative question. It published an economic model whose first dollar of revenue was gated behind ~1,000,000 consumer signups, spent its news cycle on the rhetorical layer (UN framing, "31st human right," IBM blockchain co-marketing, an acquisition), went quiet within eight months, and then persisted for seven more years as a consent-SaaS company. The company did not die. It plateaued, and nobody called it. That is the actual failure mode to defend against — and it is worse than a crash, because a crash produces a decision and a plateau produces a zombie. The market never delivers a kill signal for this shape; it delivers silence. RDCO must therefore pre-commit its own kill signal, because the environment will not supply one.
Gate 1 — the N-threshold gate (the load-bearing one). Hu-manity's revenue model contained the clause "at ~1M users we can begin to negotiate a cost structure with data buyers." Any model with that clause requires crossing a consumer-scale chasm on pre-seed capital before any revenue mechanism activates at all. Gate: RDCO's first revenue dollar must not be gated behind aggregated patient volume. If the Phase-1 pilot cannot be priced without reference to a patient-count threshold, no-go. The VBC leg is what makes this passable — a payer/ACO counterparty contracts at N=1 panel, so revenue activates at a panel size founder capital can actually reach. Concrete test: Phase 1 must produce a signed dollar from a payer/provider counterparty at <5,000 lives. If we find ourselves writing "once we have N patients, we can approach buyers," we have rewritten Hu-manity's deck.
Gate 2 — the pre-committed kill date. The establishable timeline is: raise Sept 2018, last milestone May 2019, then an eight-year plateau. Nobody ever declared failure, so nobody ever reallocated. Gate: a date-stamped re-rate checkpoint at month 18. If the bet has not produced either (a) a signed VBC-adjacent contract or (b) a term sheet from healthcare-experienced capital by that date, the verdict is no-go — not "extend." Write the date into the bet-architecture doc now, while it costs nothing, because the whole lesson of Hu-manity is that this decision is never made in the moment.
Gate 3 — the build-order inversion (an actionable finding against our own doc). Ask at architecture time: if the healthcare leg fails, what does this codebase become? Hu-manity's answer was "consent infrastructure" — which is precisely what it became, because that was its real asset all along. RDCO's outcome-measurement engine and savings-split engine are healthcare-specific and do not degrade into a horizontal product; good. But the data-ingestion MCP layer degrades cleanly into a commodity PHR — the exact 1/3 tier [[2026-07-09-patient-data-rights-startups-2024-2026-scan]] shows a competitor can buy for ~$18M. The bet-architecture doc currently lists ingestion MCPs as priority #1 in "What Ray builds." That ordering is the Hu-manity shape and should invert: build the VBC+PI economics first, ingestion second. This is the single highest-value edit this autopsy produces, and it applies to a doc we already own.
Gate 4 — legal spend is the first money out, not the last. Hu-manity spent its raise on consumer app, blockchain, and press before establishing a revenue mechanism. The bet-architecture doc already says the AKS/Beneficiary-Inducement opinion letter ($5-15K) should precede variant commitment; this autopsy argues for hardening that from intention into a gate. Gate: no more than 15% of Phase-1 capital deploys before the opinion letter is in hand. At the $100K self-fund level the letter is <15% of budget — it must be the first check written. The PI leg is the one that makes the whole structure novel; if it cannot clear AKS, everything downstream is wasted motion, and that is knowable for $15K in month one rather than $150K in month six.
Gate 5 — the rhetoric-to-revenue ratio. Within twelve months of its raise Hu-manity produced a UN appearance, the "31st human right" frame, Magna Carta press, IBM co-marketing, and TechCrunch/VentureBeat/CoinDesk coverage — and never once disclosed a revenue milestone. That asymmetry was visible in real time and was read as traction. Gate: for every press or thought-leadership artifact RDCO publishes about this bet, there must be a corresponding signed-contract or paid-pilot artifact. If the ratio runs 1:0 for two consecutive quarters, the Hu-manity tell is firing. This one is cheap to instrument and directly targets the failure mode RDCO is most temperamentally exposed to, given that we run a newsletter and publish continuously.
On the warm intro to Etwaru: recommend HOLD, and reframe the ask when it fires. The desk research already yielded the gates; the interview's marginal value is the burn curve specifically — which is private, six-to-eight years stale, and concerns a company he left to run an active, better-funded one. Retrospective founder accounts of failure are the least reliable evidence class for exactly the numbers we'd be asking for; we would likely receive a polished, retrospectively-coherent narrative rather than board-deck data. But there is a different interview that is worth the intro, and it is not the autopsy. The high-value question is not "why did it fail" — it is "who did you talk to on the payer side, and what did they say no to?" That is genuine non-public VBC-leg intelligence, it is the leg RDCO has least evidence on, it is not self-incriminating, and it is the kind of question founders enjoy answering. Timing gate: hold the intro until Phase 1 has a drafted VBC structure. Then the conversation is "react to this" — high signal, cheap for him — rather than "recount your history," which is low signal and expensive for him. Spending the intro now converts a scarce asset into a story we can mostly already infer.
Why this is in the vault
This brief converts the Hu-manity cautionary tale from a narrative into five falsifiable gates that belong in [[2026-05-10-data-sovereignty-outcome-procurement-bet-architecture]] as its Phase-0 gating section — and it produces one concrete edit against that doc's current content (inverting the build order so VBC+PI economics precede the commoditizing data-ingestion MCP layer). It also amends two factual errors in [[2026-05-18-hu-manity-co-zombie-status]] regarding Etwaru's tenure and the site's remaining rhetoric, and it establishes the honest ceiling on this research line — the burn curve is unreconstructible — so no future run re-spends effort chasing it.
Open follow-ups
- Primary read of the ROI-NJ / NJ Tech Weekly Mobeus coverage. Direct fetch 403'd; the COVID-casualty attribution rests on a search-index snippet. A primary read (or an alternate NJ trade-press source) would confirm or kill the only causal claim in the public record.
- SEC EDGAR Form D search for Hu-manity Inc. Would confirm raise date, amount, and investor count from a primary filing. Will not disclose burn. Cheap; worth closing for record hygiene.
- Did the Q1-2019 enterprise healthcare product ever ship? The 2018 coverage committed to it. Confirming it never launched would convert the "commitment-vs-silence" timeline from strong inference into established fact.
- What happened to the Betterpath assets (acquired April 2019)? A traceable write-off or resale would be the closest thing to a real spend datapoint that exists publicly.
- Does the 1M-user-threshold pattern recur in the cohort? Check whether Novellia, PicnicHealth, Seqster and Health Wizz published similar volume-gated activation thresholds. If the pattern is universal, Gate 1 generalizes from a Hu-manity lesson into a structural law of the category — a much stronger claim.
- Mobeus as the revealed-preference control. Etwaru raised 4.4x more for spatial computing than for patient data rights. Worth one pass on what healthcare-experienced capital said no to in 2019-2021 specifically, since that is the constraint RDCO inherits.
Related
- [[2026-05-18-hu-manity-co-zombie-status]]
- [[2026-05-10-data-sovereignty-outcome-procurement-bet-architecture]]
- [[2026-05-11-patient-data-sovereignty-competitor-scan]]
- [[2026-07-09-patient-data-rights-startups-2024-2026-scan]]
- [[2026-05-23-picnichealth-thumbprint-vbc-trajectory]]
- [[2026-05-22-embleema-status-check-2026]]
- [[2026-05-24-health-wizz-status-rescore]]
- [[2026-05-24-virta-health-payer-contracts-lly-thesis-input]]
- [[2026-07-06-patient-side-cac-data-sovereignty-care-brand]]
Sources
Vault:
~/rdco-vault/06-reference/research/2026-05-18-hu-manity-co-zombie-status.md(parent)~/rdco-vault/01-projects/health-and-longevity/2026-05-10-data-sovereignty-outcome-procurement-bet-architecture.md~/rdco-vault/06-reference/research/2026-05-11-patient-data-sovereignty-competitor-scan.md~/rdco-vault/06-reference/research/2026-07-09-patient-data-rights-startups-2024-2026-scan.md~/rdco-vault/06-reference/research/2026-05-23-picnichealth-thumbprint-vbc-trajectory.md~/rdco-vault/06-reference/research/2026-05-22-embleema-status-check-2026.md~/rdco-vault/06-reference/research/2026-05-24-health-wizz-status-rescore.md~/rdco-vault/06-reference/research/2026-05-24-virta-health-payer-contracts-lly-thesis-input.md~/rdco-vault/06-reference/research/2026-07-06-patient-side-cac-data-sovereignty-care-brand.md
Web (accessed 2026-07-17):
- TechCrunch — Hu-manity launches app giving consumers legal control over medical data (2018-09-06) — WebFetch verified; source of the 25,000-title and 1M-user thresholds and the Q1-2019 enterprise commitment
- hu-manity.co homepage — WebFetch verified 2026-07-17; footer "© 2022", Privacy Experience™, zero healthcare language, no #My31 mention
- Crunchbase — Richie Etwaru person profile — Chairman, Co-founder & CEO @ Mobeus
- ROI-NJ — Tech Trends: Mobeus co-founder Richie Etwaru (2023-04-05) — HTTP 403 on direct fetch; snippet-only, MEDIUM confidence
- Forbes Technology Council — Richie Etwaru, Co-Founder & CEO, Mobeus
- LinkedIn — Richie Etwaru ("CEO @Mobeus")
- Crunchbase — Hu-manity.co organization profile — operating status "Active"
- Tracxn — Hu-manity.co profile — 20 employees as of 2024-07-01